Discover Clinical Trials at City of Hope
Use the search and filter features below to discover and explore relevant clinical trials underway at City of Hope®. Please reach out to your cancer care team who can help you find out whether you qualify for any of our open clinical trials.
465 results
A Phase I/II, Multicenter, Open-label Study of IBI3003 in Participants with Relapsed or Refractory Multiple Myeloma (CIBI3003A101)
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 23~116 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma.
Location Name
Status
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies_BeiGene BGB-16673-101_COH ATL
Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Location Name
Status
Atlanta
Open to Accrual
Targeted Agent and Profiling Utilization Registry (TAPUR) Study_ASCO TAPUR_COH ATL
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact [email protected], or if a patient, your nearest participating TAPUR site (see participating centers).
********************************************************************
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
********************************************************************
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact [email protected], or if a patient, your nearest participating TAPUR site (see participating centers).
********************************************************************
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
********************************************************************
Location Name
Status
Atlanta
Open to Accrual
Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients with Resectable Colon Cancer (NEST3)
This phase II trial tests how well giving botensilimab and balstilimab prior or to surgery (neoadjuvent) works for the treatment of colorectal cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that can be removed by surgery (resectable) colorectal cancer. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving botensilimab and balstilimab before surgery may make the tumor smaller. Giving neoadjuvant botensilimab and balstilimab may be effective for the treatment of advanced resectable colorectal cancer.
Location Name
Status
Atlanta
Open to Accrual
Chicago
Open to Accrual
Corona
Open to Accrual
Downtown Chicago
Pending
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
Long Beach Elm
Open to Accrual
Newport Beach Lido
Pending
Phoenix
Open to Accrual
Seacliff
Open to Accrual
South Pasadena
Open to Accrual
Upland
Open to Accrual
Phase 1b study of glofitamab in CNS lymphoma
This phase Ib trial tests the safety and side effects of glofitamab after pre-treatment with obinutuzumab and how well they work in treating patients with central nervous system (CNS) lymphoma. Glofitamab is a bispecific antibody that can bind to two different antigens (substances that cause the body to make a specific immune response) at the same time. Glofitamab binds to CD20 on lymphoma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Obinutuzumab can also be administered as a pre-treatment to make glofitamab safer and more tolerable. Giving glofitamab with obinutuzumab pre-treatment may be safe, tolerable, and/or effective in treating patients with CNS lymphoma.
Location Name
Status
Duarte
Open to Accrual
A First in Human Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-88549968, a T-cell redirecting Bi-specific Antibody Targeting Mutated CALR expression in in Myeloproliferative Neoplasms
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s) in part 2 (Cohort Expansion). For U.S. sites: the purpose of this study is to characterize the safety and to determine the RP2D(s) and optimal dosing schedule(s) of JNJ-88549968 in Part 1 and part 1b (Dose Escalation), and to characterize the safety of JNJ-88549968 at the RP2D(s) in Part 2 and part 2b (Cohort Expansion), when given as monotherapy in essential thrombocythemia (ET) or myelofibrosis (MF), and with ruxolitinib or momelotinib in MF only.
Location Name
Status
Chicago
Open to Accrual
Duarte
Open to Accrual
Phoenix
Open to Accrual
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/4 Dual Degrader NKT5097 in Adults with Advanced/Metastatic Solid Tumors
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include:
* What is the recommended dose for expansion and/or Phase 2, for both monotherapy and in combination with ET
* What medical issues/symptoms do participants experience when taking NKT5097 as monotherapy as well as in combination with ET
* What is the recommended dose for expansion and/or Phase 2, for both monotherapy and in combination with ET
* What medical issues/symptoms do participants experience when taking NKT5097 as monotherapy as well as in combination with ET
Location Name
Status
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
ctDNA Testing in Resectable Stage II-IV Colorectal Cancer Patients: a Head-to-Head Performance Comparison
This clinical trial compares minimal residual disease (MRD) testing with the Haystack blood test (assay) to the Signatera® assay for the early detection of the cancer returning (cancer recurrence) in patients with stage II-IV colorectal cancer (CRC) that can be removed by surgery (resectable). MRD testing looks for evidence of remaining tumor following treatment that is only apparent using highly sensitive techniques. There are few effective tools available outside of imaging to identify CRC patients with MRD who may be at the highest risk for cancer recurrence after surgery. Early detection of CRC recurrence after surgery is important, as it may increase the chance of curative (ability to cure) outcomes for patients with cancer recurrence. Currently, the Signatera assay is used to monitor whether CRC recurs after surgery, however it is not a very sensitive test. Early work with the Haystack assay suggests it may be more sensitive than the Signatera assay, which may be more effective for the early detection of cancer recurrence in patients with resectable stage II-IV CRC.
Location Name
Status
Antelope Valley
Open to Accrual
Atlanta
Open to Accrual
Chicago
Open to Accrual
Corona
Open to Accrual
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
Long Beach Elm
Open to Accrual
Long Beach Worsham
Pending
Newport Beach Lido
Open to Accrual
Phoenix
Open to Accrual
Seacliff
Open to Accrual
South Bay
Open to Accrual
South Pasadena
Open to Accrual
Upland
Open to Accrual
A Phase III, Randomized Study Of Daratumumab, Cyclophosphamide, Bortezomib
and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation And Daratumumab Maintenance In Patients With Newly Diagnosed AL Amyloidosis
and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation And Daratumumab Maintenance In Patients With Newly Diagnosed AL Amyloidosis
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients with newly diagnosed amyloid light chain (AL) amyloidosis. Melphalan is a chemotherapy given prior to a stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. The stem cells are then returned to the patients to replace the blood forming cells that were destroyed by the chemotherapy. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs, such as cyclophosphamide and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to lower the body's immune response to help stop the growth of cancer cells. Giving a stem cell transplant with melphalan after Dara-VCD may kill more cancer cells in patients with newly diagnosed AL amyloidosis.
Location Name
Status
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
Phoenix
Open to Accrual
A Phase 2 Study of Loncastuximab Tesirine plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, loncastuximab, linked to a toxic agent called tesirine. Loncastuximab attaches to anti-CD19 cancer cells in a targeted way and delivers tesirine to kill them. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving loncastuximab tesirine with mosunetuzumab may help treat patients with relapsed or refractory diffuse large B-cell lymphoma.
Location Name
Status
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
Note: Some clinical trials at City of Hope may not be listed. Please reach out to your cancer care team to identify additional trials for which you may qualify.